Please Wait.....
Report
Global Infectious Disease Therapeutics Market Report and Forecast 2024-2032
Market Report (7 days) I 2024-02-06 I 180 Pages I EMR Inc.
Global Infectious Disease Therapeutics Market Report and Forecast 2024-2032
Global Infectious Disease Therapeutics Market Outlook
The global infectious disease therapeutics market size was valued at USD 109.8 billion in 2023, driven by increasing prevalence of antimicrobial-resistant pathogens across the globe. The market size is anticipated to grow at a CAGR of 6.3% during the forecast period of 2024-2032 to achieve a value of USD 189.7 billion by 2032.
Infectious Disease Therapeutics: Introduction
Infectious disease therapeutics refers to the treatment and management of diseases caused by pathogens such as bacteria, viruses, fungi, or parasites. This field encompasses a wide range of medications, including antibiotics, antivirals, antifungals, and antiparasitics, tailored to target specific infectious agents. The choice of therapy depends on the type of pathogen, its resistance patterns, and the patient's health status. Recent advances include the development of novel drugs, vaccines, and combination therapies to combat drug-resistant strains and emerging infectious diseases.
Key Trends in the Global Infectious Disease Therapeutics Market
One of the most pressing trends is the increasing prevalence of antimicrobial-resistant pathogens, which is driving research and development efforts to discover new antimicrobial agents and alternative therapies.
Recent years have seen significant progress in vaccine technology, including mRNA vaccines, which offer rapid development opportunities for infectious diseases, as evidenced by the COVID-19 pandemic response.
There's a growing interest in developing combination therapies that use more than one drug to treat infectious diseases, aiming to enhance efficacy and prevent the development of resistance.
The emergence of new pathogens and re-emergence of old ones, such as Ebola and Zika, have highlighted the need for continuous surveillance, rapid diagnostic methods, and the development of flexible therapeutic platforms.
The market is seeing a shift towards personalized medicine approaches, where treatments are tailored based on individual patient profiles and specific pathogen characteristics, guided by advanced diagnostics.
The integration of point-of-care diagnostic tools is becoming more prevalent, allowing for quicker diagnosis and the initiation of targeted therapies, improving patient outcomes.
International collaborations and funding initiatives are crucial in combating infectious diseases, especially in low- and middle-income countries. These efforts focus on vaccine distribution, improving access to treatments, and strengthening healthcare systems.
Digital tools and telemedicine are increasingly used for monitoring infectious disease outbreaks, improving treatment adherence, and managing patient care remotely, especially in regions with limited healthcare access.
Global Infectious Disease Therapeutics Market Segmentation
Market Breakup by Disease
- HIV/AIDS
- Influenza
- Hepatitis
- Tuberculosis
- Malaria
- Others
Market Breakup by Infection Type
- Bacterial
- Viral
- Fungal
- Parasitic
- Others
Market Breakup by Treatment Type
- Drugs
- Vaccines
Market Breakup by Mode of Treatment
- Oral
- Parenteral
- Topical
- Others
Market Breakup by Distribution Channel
- Hospitals
- Clinics
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Infectious Disease Therapeutics Market Overview
In North America, the infectious disease therapeutics market is characterized by advanced healthcare infrastructure and a strong focus on research and development. The region sees significant investment in the development of new antibiotics and antivirals, particularly to address drug-resistant infections and emerging diseases like COVID-19. There's also a growing emphasis on vaccination programs and the adoption of combination therapies to enhance treatment efficacy.
Europe's market benefits from robust public health systems and coordinated efforts across countries to manage infectious diseases. The region focuses on antimicrobial stewardship to combat antibiotic resistance and supports the development of novel therapeutics through regulatory incentives. Collaboration between the European Union members for vaccine procurement and distribution, especially for pandemic preparedness, is a key trend.
The Asia-Pacific region exhibits rapid growth in the infectious disease therapeutics market, driven by increasing healthcare expenditure and a high burden of infectious diseases. Countries like China and India are significant contributors to the market, focusing on both the production of generic medications and the development of new treatments. Efforts to improve healthcare access and the rising demand for vaccines and advanced therapies contribute to market dynamics.
Global Infectious Disease Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- Pfizer Inc.
- GlaxoSmithKline plc.
- Merck & Co.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca Plc
- Mylan N.V.
- Novartis AG
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Astellas Pharma
- AbbVie Inc.
- Boehringer Ingelheim GmbH
- Gilead Sciences
- Johnson & Johnson
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Infectious Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Infectious Disease Epidemiology Analysis
5.1 Global Infectious Disease Epidemiology Scenario Overview (2017-2032)
5.2 North America Infectious Disease Epidemiology Scenario and Forecast (2017-2032)
5.3 Europe Infectious Disease Epidemiology Scenario and Forecast (2017-2032)
5.4 Asia Pacific Infectious Disease Epidemiology Scenario and Forecast (2017-2032)
5.5 Latin America Infectious Disease Epidemiology Scenario and Forecast (2017-2032)
5.6 Middle East & Africa Infectious Disease Epidemiology Scenario and Forecast (2017-2032)
6 Global Infectious Disease Therapeutics Market Overview
6.1 Global Infectious Disease Therapeutics Market Historical Value (2017-2023)
6.2 Global Infectious Disease Therapeutics Market Forecast Value (2024-2032)
7 Global Infectious Disease Therapeutics Market Landscape*
7.1 Global Infectious Disease Therapeutics Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Infectious Disease Therapeutics Product Landscape
7.2.1 Analysis by Mode of Treatment
7.2.2 Analysis by Infection Type
7.2.3 Analysis by Indication
8 Infectious Disease Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Infectious Disease Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter's Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Infectious Disease Therapeutics Market Segmentation (2017-2032)
11.1 Global Infectious Disease Therapeutics Market (2017-2032) by Disease
11.1.1 Market Overview
11.1.2 HIV/AIDS
11.1.3 Influenza
11.1.4 Hepatitis
11.1.5 Tuberculosis
11.1.6 Malaria
11.1.7 Others
11.2 Global Infectious Disease Therapeutics Market (2017-2032) by Infection Type
11.2.1 Market Overview
11.2.2 Bacterial
11.2.3 Viral
11.2.4 Fungal
11.2.5 Parasitic
11.2.6 Others
11.3 Global Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
11.3.1 Market Overview
11.3.2 Drugs
11.3.3 Vaccines
11.4 Global Infectious Disease Therapeutics Market (2017-2032) by Mode of Treatment
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Topical
11.4.5 Others
11.5 Global Infectious Disease Therapeutics Market (2017-2032) by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Clinics
11.5.4 Others
11.6 Global Infectious Disease Therapeutics Market (2017-2032) by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Infectious Disease Therapeutics Market
12.1 North America Infectious Disease Therapeutics Market (2017-2032) by Disease
12.1.1 Market Overview
12.1.2 HIV/AIDS
12.1.3 Influenza
12.1.4 Hepatitis
12.1.5 Tuberculosis
12.1.6 Malaria
12.1.7 Others
12.2 North America Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
12.2.1 Market Overview
12.2.2 Drugs
12.2.3 Vaccines
12.3 North America Infectious Disease Therapeutics Market (2017-2032) by Country
12.3.1 United States of America
12.3.2 Canada
13 Europe Infectious Disease Therapeutics Market
13.1 Europe Infectious Disease Therapeutics Market (2017-2032) by Disease
13.1.1 Market Overview
13.1.2 HIV/AIDS
13.1.3 Influenza
13.1.4 Hepatitis
13.1.5 Tuberculosis
13.1.6 Malaria
13.1.7 Others
13.2 Europe Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
13.2.1 Market Overview
13.2.2 Drugs
13.2.3 Vaccines
13.3 Europe Infectious Disease Therapeutics Market (2017-2032) by Country
13.3.1 United Kingdom
13.3.2 Germany
13.3.3 France
13.3.4 Italy
13.3.5 Others
14 Asia Pacific Infectious Disease Therapeutics Market
14.1 Asia Pacific Infectious Disease Therapeutics Market (2017-2032) by Disease
14.1.1 Market Overview
14.1.2 HIV/AIDS
14.1.3 Influenza
14.1.4 Hepatitis
14.1.5 Tuberculosis
14.1.6 Malaria
14.1.7 Others
14.2 Asia Pacific Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
14.2.1 Market Overview
14.2.2 Drugs
14.2.3 Vaccines
14.3 Asia Pacific Infectious Disease Therapeutics Market (2017-2032) by Country
14.3.1 China
14.3.2 Japan
14.3.3 India
14.3.4 ASEAN
14.3.5 Australia
14.3.6 Others
15 Latin America Infectious Disease Therapeutics Market
15.1 Latin America Infectious Disease Therapeutics Market (2017-2032) by Disease
15.1.1 Market Overview
15.1.2 HIV/AIDS
15.1.3 Influenza
15.1.4 Hepatitis
15.1.5 Tuberculosis
15.1.6 Malaria
15.1.7 Others
15.2 Latin America Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
15.2.1 Market Overview
15.2.2 Drugs
15.2.3 Vaccines
15.3 Latin America Infectious Disease Therapeutics Market (2017-2032) by Country
15.3.1 Brazil
15.3.2 Argentina
15.3.3 Mexico
15.3.4 Others
16 Middle East and Africa Infectious Disease Therapeutics Market
16.1 Middle East and Africa Infectious Disease Therapeutics Market (2017-2032) by Disease
16.1.1 Market Overview
16.1.2 HIV/AIDS
16.1.3 Influenza
16.1.4 Hepatitis
16.1.5 Tuberculosis
16.1.6 Malaria
16.1.7 Others
16.2 Middle East and Africa Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
16.2.1 Market Overview
16.2.2 Drugs
16.2.3 Vaccines
16.3 Middle East and Africa Infectious Disease Therapeutics Market (2017-2032) by Country
16.3.1 Saudi Arabia
16.3.2 United Arab Emirates
16.3.3 Nigeria
16.3.4 South Africa
16.3.5 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Pfizer Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 GlaxoSmithKline plc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 Merck & Co.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 F. Hoffmann-La Roche Ltd.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 AstraZeneca Plc
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Mylan N.V.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Novartis AG
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Sanofi SA
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Takeda Pharmaceutical Company Limited
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Astellas Pharma
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 AbbVie Inc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 Boehringer Ingelheim GmbH
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 Gilead Sciences
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 Johnson & Johnson
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
List not exhaustive
23 Global Infectious Disease Therapeutics Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security